🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

H.C. Wainwright ups ASP Isotopes shares target, confident in continued revenue

EditorEmilio Ghigini
Published 04/17/2024, 07:14 PM
ASPI
-

On Wednesday, H.C. Wainwright maintained a Buy rating on ASP Isotopes Inc. (NASDAQ: ASPI) and increased the share price target to $5.50 from the previous $5.25. The adjustment follows the company's recent filing of its annual financial results.

ASP Isotopes Inc. reported its 2023 financial outcomes on April 10, revealing revenues of $0.4 million and a net loss of $16.3 million, or a loss of $0.49 per share. This reflects a widened net loss from the $4.9 million, or $0.18 per share, recorded in 2022. The increase in net loss is attributable to a spike in Selling, General and Administrative (SG&A) expenses to $15.4 million, up from $3.8 million the previous year.

Despite the increase in net loss, the firm reduced its Research and Development (R&D) expenditures by 40% year-over-year to $0.8 million, which provided some offset to the rising SG&A costs. ASP Isotopes' revenue stems from its sale of nuclear medical doses for PET scanning, a segment that was bolstered by the acquisition of a 51% stake in PET Labs Pharmaceuticals, a private entity, in October of the previous year.

Looking ahead, H.C. Wainwright anticipates that ASP Isotopes will continue to generate revenue. The firm emphasized the management's success in de-risking operations over the past year. The analyst's statement underscored the expectation of ongoing revenue generation and operational stability for the company.

InvestingPro Insights

Following H.C. Wainwright's optimistic outlook on ASP Isotopes Inc. (NASDAQ: ASPI), real-time data from InvestingPro provides additional context for investors. The company's market capitalization currently stands at $154.6 million. Despite not being profitable over the last twelve months, ASPI has experienced a high return over the last year, with a 371.18% one-year price total return. This impressive performance is supported by a strong three-month price total return of 101.57%.

InvestingPro Tips indicate that while ASPI operates with a moderate level of debt, it is trading at a high Price / Book multiple of 21.73 as of the last twelve months ending Q3 2023. Moreover, the company does not pay a dividend, which may be a consideration for income-focused investors. For those seeking a deeper analysis, InvestingPro offers additional tips and metrics on ASPI, which can be found at https://www.investing.com/pro/ASPI. Investors can use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, unlocking further insights to aid in their investment decisions. Currently, there are 7 additional InvestingPro Tips available for ASPI, providing a comprehensive view of the company's financial health and market performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.